DLL3 and small cell lung carcinoma: Other TCEs and molecules targeting DLL3, including HPN328, BI 764532 and QLS31904, have entered phase I clinical trials and are being investigated in DLL3‐positive SCLC and other NE tumours.232, 233, 234, 235